KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Restructuring Costs: 2016-2024

Historic Restructuring Costs for Travere Therapeutics (TVTX) over the last 1 years, with Dec 2024 value amounting to $1.4 million.

  • Travere Therapeutics' Restructuring Costs fell 87.69% to $1.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.4 million, marking a year-over-year decrease of 86.99%. This contributed to the annual value of $2.4 million for FY2024, which is 78.60% down from last year.
  • According to the latest figures from Q4 2024, Travere Therapeutics' Restructuring Costs is $1.4 million, which was up 1,040.65% from $123,000 recorded in Q3 2024.
  • Over the past 5 years, Travere Therapeutics' Restructuring Costs peaked at $11.4 million during Q4 2023, and registered a low of $123,000 during Q3 2024.
  • Its 2-year average for Restructuring Costs is $2.8 million, with a median of $653,000 in 2024.
  • Data for Travere Therapeutics' Restructuring Costs shows a maximum YoY plummeted of 87.69% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Travere Therapeutics' Restructuring Costs stood at $11.4 million in 2023, then crashed by 87.69% to $1.4 million in 2024.
  • Its last three reported values are $1.4 million in Q4 2024, $123,000 for Q3 2024, and $653,000 during Q2 2024.